专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060228370A1 7a5/Prognostin and use thereof for the diagnostic and therapy of tumors 有权
标题翻译： 7a5 /预后蛋白及其用于诊断和治疗肿瘤的用途
公开(公告)号：US20060228370A1
公开(公告)日：2006-10-12
申请号：US10564823
申请日：2004-07-19
申请人： Ulrike Stein , Holger Schwabe , Wolfgang Walther , Peter Schlag
发明人： Ulrike Stein , Holger Schwabe , Wolfgang Walther , Peter Schlag
IPC分类号： C12Q1/68 , G01N33/574 , C07H21/04 , C12P21/06 , A61K39/00 , C07K14/82 , C07K16/30
CPC分类号： C07K14/47 , A61K39/00 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/154 , G01N33/57419
摘要： The present invention refers to the nucleic acid sequence encoding for the polypeptide of 7a5/Prognostin and to its uses, in particular for the tumour diagnostics and tumour therapy of metastasising tumours.
摘要翻译：本发明涉及编码7a5 /预后蛋白多肽的核酸序列及其用途，特别是转移肿瘤的肿瘤诊断和肿瘤治疗。

2. 发明申请

US20140294957A1 NICLOSAMIDE FOR THE TREATMENT OF CANCER METASTASIS 审中-公开
标题翻译：用于治疗癌症METASASIS的NICOLOSAMIDE
公开(公告)号：US20140294957A1
公开(公告)日：2014-10-02
申请号：US14112521
申请日：2012-04-18
申请人： Ulrike Stein , Wolfgang Walther , Ulrike Sack , Robert Shoemaker , Dominic Scudiero , Peter M Schlag
发明人： Ulrike Stein , Wolfgang Walther , Ulrike Sack , Robert Shoemaker , Dominic Scudiero , Peter M Schlag
IPC分类号： A61K31/167
CPC分类号： A61K31/167 , A61K31/4035 , A61K45/06
摘要： The invention relates to niclosamide and derivates thereof, which effectively inhibit transcription of the S100A4 gene, resulting in inhibition and/or reduction of S100A4-induced cell motility, invasiveness, metastasis and proliferation of human cancer cells.
摘要翻译：本发明涉及有效抑制S100A4基因转录的奈沙酰胺及其衍生物，导致S100A4诱导的细胞运动性，侵袭性，转移和人类癌细胞增殖的抑制和/或降低。

3. 发明授权

US5968735A Vector for the expression of therapy-relevant genes 失效
标题翻译：用于表达治疗相关基因的载体
公开(公告)号：US5968735A
公开(公告)日：1999-10-19
申请号：US439814
申请日：1995-05-12
申请人： Ulrike Stein , Wolfgang Walther
发明人： Ulrike Stein , Wolfgang Walther
IPC分类号： C12N15/85 , C12P21/00 , C12Q1/68
CPC分类号： C12N15/85 , C12N2830/002 , C12N2830/008 , C12N2830/85
摘要： A vector for expression of relevant therapeutic genes in mammalian cells which utilizes the mdr promoter, and optionally, the mdr enhancer, operably linked to the therapeutic gene.
摘要翻译：用于在哺乳动物细胞中表达相关治疗基因的载体，其利用可操作地连接到治疗基因的mdr启动子和任选的mdr增强子。

4. 发明申请

US20120276539A1 USE OF METASTASIS PROGRESSOR S100A4 TRANSCRIPTS IN BODY FLUIDS OF COLORECTAL AND GASTRIC CANCER PATIENTS 审中-公开
标题翻译： METASASIS进展剂S100A4转录物在体液和胃癌患者体液中的应用
公开(公告)号：US20120276539A1
公开(公告)日：2012-11-01
申请号：US13509460
申请日：2010-03-19
申请人： Ulrike Stein , Pia Herrmann , Susen Burock , Peter Michael Schlag
发明人： Ulrike Stein , Pia Herrmann , Susen Burock , Peter Michael Schlag
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118
摘要： Transcript quantification of the metastasis progressor S100A4 is performed in body fluids. Methods, assays and kits relying on this quantification are disclosed that have diagnostic and/or prognostic applications in colorectal and gastric cancer patients.
摘要翻译：在体液中进行转移进展S100A4的转录物定量。公开了依赖于该定量的方法，测定和试剂盒，其在结肠直肠癌和胃癌患者中具有诊断和/或预后应用。

5. 发明授权

US07297535B2 Use of the human LRP/MVP promotor for a vector that can be induced by therapy 有权
标题翻译：使用人类LRP / MVP启动子可以通过治疗诱导的载体
公开(公告)号：US07297535B2
公开(公告)日：2007-11-20
申请号：US10416209
申请日：2001-11-08
申请人： Ulrike Stein , Christian Lange , Wolfgang Walther , Peter Michael Schlag
发明人： Ulrike Stein , Christian Lange , Wolfgang Walther , Peter Michael Schlag
IPC分类号： C12N15/85 , C07H21/04
CPC分类号： A61K48/0058
摘要： Embodiments of the invention relate to a vector system that allows one to induce expression of therapeutically relevant genes in mammalian cells. Such a vector system may be useful for medicine and in the pharmaceutical industry. A vector comprises base structures suitable for expression in mammalian cells as well as either the whole of or parts of the gene promoter of human Major Vault Protein (MVP), also known as LRP (Lung Resistance Protein) as well as a gene encoding a therapeutic protein or non-translated RNA. As the MVP promoter is inducible by therapy (for example, but not limited to, chemotherapy or hyperthermia), the vector system provides combinations of therapeutic methods with gene therapy in a controlled fashion, resulting in more efficient treatment of tumor diseases.
摘要翻译：本发明的实施方案涉及允许诱导哺乳动物细胞中治疗相关基因表达的载体系统。这种载体系统可用于医药和制药工业。载体包含适于在哺乳动物细胞中表达的碱基结构以及人类大肠蛋白蛋白（MVP）的基因启动子的全部或部分，也称为LRP（肺抗性蛋白），以及编码治疗蛋白质或非翻译的RNA。由于MVP启动子可通过治疗（例如但不限于化学疗法或高热）诱导，所以载体系统以受控的方式提供治疗方法与基因治疗的组合，从而更有效地治疗肿瘤疾病。

6. 发明授权

US07851168B2 7a5/prognostin and use thereof for the diagnostic and therapy of tumors 有权
标题翻译： 7a5 / prognostin及其用于肿瘤诊断和治疗的用途
公开(公告)号：US07851168B2
公开(公告)日：2010-12-14
申请号：US10564823
申请日：2004-07-19
申请人： Ulrike Stein , Holger Schwabe , Wolfgang Walther , Peter Michael Schlag
发明人： Ulrike Stein , Holger Schwabe , Wolfgang Walther , Peter Michael Schlag
IPC分类号： G01N33/574
CPC分类号： C07K14/47 , A61K39/00 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/154 , G01N33/57419
摘要： The present invention refers to the nucleic acid sequence encoding for the polypeptide of 7a5/Prognostin and to its uses, in particular for the tumour diagnostics and tumour therapy of metastasising tumours.
摘要翻译：本发明涉及编码7a5 /预后蛋白多肽的核酸序列及其用途，特别是转移肿瘤的肿瘤诊断和肿瘤治疗。

7. 发明授权

US06582690B1 Process for treating tumors with cytotoxic substances 失效
标题翻译：用细胞毒性物质治疗肿瘤的方法
公开(公告)号：US06582690B1
公开(公告)日：2003-06-24
申请号：US09273066
申请日：1999-03-19
申请人： Ulrike Stein , Wolfgang Walther , Peter Schlag
发明人： Ulrike Stein , Wolfgang Walther , Peter Schlag
IPC分类号： A61K3821
CPC分类号： A61K38/191 , A61K38/2013
摘要： The invention concerns a cytotoxic, MDR-associated substance for producing a therapeutic agent for tumor therapy, which is characterized by a) the tumor cells of a tumor patient are chemosensitized with a cytokine, b) the scope of expression of one or more MDR-associate genes (e.g. mdrl, Mrp, Lrp) in the tumor tissues of the patient is determined according to the beginning of the cytokine treatment, c) the time domain is determined, in which the expression of one or more MDR-associate genes is substantially reduced by the cytokine treatment, d) the patient is treated in the determined time domain (“therapeutic window”) with a therapeutically effective amount of a cytotoxic, MDR-associated substance, the effectiveness of which is influenced (enhanced) by the expression of one or more MDR-associate genes. The use of said substance leads to an improved tumor therapy.
摘要翻译：本发明涉及用于产生用于肿瘤治疗的治疗剂的细胞毒性MDR相关物质，其特征在于：a）肿瘤患者的肿瘤细胞用细胞因子进行化学敏化，b）一种或多种MDR- 根据细胞因子治疗的开始确定患者肿瘤组织中的关联基因（例如mdr1，Mrp，Lrp），c）确定一个或多个MDR相关基因的表达基本上在时间域通过细胞因子治疗减少d）在确定的时间域（“治疗窗口”）中用治疗有效量的细胞毒性MDR相关物质治疗患者，其效力受到（增强）的表达的影响一个或多个MDR相关基因。所述物质的使用导致改善的肿瘤治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式